Clinical Challenges

Nail Toxicity Associated With Paclitaxel Treatment for Ovarian Cancer

Karen K. Swenson

Elaine M. Bell

Julia Nissen

ovarian neoplasms, chemotherapy
ONF 2012, 40(1), 17-19. DOI: 10.1188/13.ONF.17-19

A 57-year-old woman named C. B. began experiencing abdominal pain and bloating. She presented to her primary physician with these symptoms, and her physician palpated an adenexal mass on pelvic examination. That prompted a computed tomography (CT) scan of the abdomen and pelvis, which demonstrated omental thickening as well as a mildly enlarged left ovary. After initial consultation with a gynecologic oncologist, C. B. was taken to surgery and a total abdominal hysterectomy bilateral salpingo-oophorectomy omentectomy partial bowel resection, and pelvic and periaortic lymph node dissection were performed. C. B. was diagnosed with stage IV ovarian cancer involving the omentum, pelvic lymph nodes, and bowel wall and was subsequently referred for postoperative chemotherapy.

Jump to a section


    Bristol-Myers Squibb. (2011). Taxol® (paclitaxel) injection [Package insert]. Retrieved from
    Can, G., Aydiner, A., & Cavdar, I. (2012). Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. European Journal of Oncology Nursing, 16, 270-275. doi:10.1016/j.ejon.2011.06.007
    Chew, L., & Chuen, V. S. (2009). Cutaneous reaction associated with weekly docetaxel administration. Journal of Oncology Pharmacy Practice, 15, 29-34. doi:10.1177/1078155208096111
    Chitapanarux, I., Kamnerdsupaphon, P., Tharavichitkul, E., Lorvidhaya, V., Trakultivakorn, H., Srisukho, S., … Sukthomya, V. (2012). Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 8, 76-82. doi:10.1111/j.1743-7563.2011.01467.x
    Daniel, C. R., 3rd, Daniel, M. P., Daniel, J., Sullivan, S., & Bell, F. E. (2004). Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen. Cutis: Cutaneous Medicine for the Practitioner, 73, 81-85.
    DeGiorgi, U., Rosti, G., Monti, M., Frassineti, G. L., & Marangolo, M. (2003). Onycholysis secondary to multiple paclitaxel one-hour infusions: Possible role for its vehicle (Cremophor EL). Annals of Oncology, 14, 1588-1589. doi:10.1093/annonc/mdg419
    Flory, S. M., Solimando, D. A., Jr., Webster, G. F., Dunton, C. J., Neufeld, J. M., & Haffey, M. B. (1999). Onycholysis associated with weekly administration of paclitaxel. Annals of Pharmacotherapy, 33, 584-586. doi:10.1345/aph.18307
    Ghetti, E., Piraccini, B. M., & Tosti, A. (2003). Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). Journal of European Academy of Dermatology and Venereology, 17, 459-460. doi:10.1046/j.1468-3083.2003.00774.x
    Gilbar, P., Hain, A., & Peereboom, V. M. (2009). Nail toxicity induced by cancer chemotherapy. Journal of Oncology Pharmacy Practice, 15, 143-155. doi:10.1177/1078155208100450
    Gori, S., Colozza, M., Mosconi, A. M., Franceschi, E., Basurto, C., Cherubini, R., … Tonato, M. (2004). Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer, 90, 36-40.
    Hussain, S., Anderson, D. N., Salvatti, M. E., Adamson, B., McManus, M., & Braverman, A. S. (2000). Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer, 88, 2367-2371. doi:10.1002/(SICI)1097-0142 (20000515)88:10
    Mackay-Wiggan, J., Nair, K. G., & Halasz, C. L. (2003). Onycholysis associated with paclitaxel. Cutis: Cutaneous Medicine for the Practitioner, 71, 229-232.
    Markman, M., Hall, J., Spitz, D., Weiner, S., Carson, L., Van Le, L., … Baker, M. (2002). Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology, 20, 2365-2369. doi:10.1200/JCO.2002.09.130
    Mauri, D., Kamposioras, K., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., … Polyzos, N. P. (2010). Overall survival benefit for weekly versus three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treatment Review, 36, 69-74. doi:10.1016/j.ctrv.2009.10.006
    MedicineNet. (1996-2012). MedTerms™. Retrieved from
    Miladinovic, D. L., Mihajilov-Krstev, T. M., Nikolic, N. D., Miladinovic, L. C., & Cvetkovic, O. G. (2012). Investigation of the chemical composition-antibacterial activity relationship of essential oils by chemometric methods. Analytical and Bioanalytical Chemistry, 403, 1007-1018. doi:10.1007/s00216-012-5866-1
    Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., … Puglisi, F. (2003). Taxane-induced nail changes: Incidence, clinical presentation and outcome. Annals of Oncology, 14, 333-337. doi:10.1093/annonc/mdg050
    Minutilli, E., Izzo, F., Natoli, G., Psaila, A., DiFilippo, F., & Terzoli, E. (2006). Paclitaxel-induced nail changes: Possible role of its vehicle (Cremophor EL). European Journal of Dermatology, 16, 693-694.
    National Institutes of Health. (2012). Retrieved from
    Paul, L. J., & Cohen, P. R. (2012). Paclitaxel-associated subungual pyogenic granuloma: Report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. Journal of Drugs in Dermatology, 11, 262-268.
    Roh, M. R., Cho, J. Y., & Lew, W. (2007). Docetaxel-induced onycholysis: The role of subungual hemorrhage and suppuration. Yonsei Medical Journal, 48, 124-126. doi:10.3349/ymj.2007.48.1.124
    Sanofi Oncology. (2012). Taxotere® (docetaxel) injection concentrate. Retrieved from
    Scotte, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., … Oudard, S. (2008). Matched case control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer, 112, 1625-1631. doi:10.1002/cncr.23333
    Shin, E., Ishotobi, M., Hiraoia, M., Kazumasa, F., Hideyuki, M., Nishisho, I., … Tosimasa, T. (2000). Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer. Anticancer Research, 20(6C), 4721-4726.
    Sorbe, B., Graflund, M., Horvath, G., Swahn, M., Boman, K., Bangshoj, R., … Malmstrom, H. (2012). Phase II study of docetaxel weekly in combination with carboplatin every three weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer. International Journal of Gynecological Cancer, 22, 47-53.
    Wasner, G., Hilpert, F., Schattschneider, J., Binder, A., Pfisterer, J., & Baron, R. (2002). Docetaxel-induced nail changes—A neurogenic mechanism: A case report. Journal of Neuro-Oncology, 58, 167-174.